KMID : 0191120200350060036
|
|
Journal of Korean Medical Science 2020 Volume.35 No. 6 p.36 ~ p.36
|
|
Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
|
|
Park Gil-Chun
Hwang Shin Kim Myoung-Soo Jung Dong-Hwan Song Gi-Won Lee Kwang-Woong Kim Jong-Man Lee Jae-Geun Ryu Je-Ho Choi Dong-Lak Wang Hee-Jung Kim Bong-Wan Kim Dong-Sik Nah Yang-Won You Young-Kyoung Kang Koo-Jeong Yu Hee-Chul Park Yo-Han Lee Kyung-Jin Kim Yun-Kyu
|
|
Abstract
|
|
|
Background: Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population.
Methods: Korean Organ Transplantation Registry (KOTRY) database and additionally collected data (n = 326) were analyzed with special reference to types of HBV prophylaxis.
Results: The study cohort comprised 267 cases of living-donor LT and 59 cases of deceased-donor LT. Hepatocellular carcinoma (HCC) was diagnosed in 232 (71.2%) of these subjects. Antiviral agents were used in 255 patients (78.2%) prior to LT. HBV DNA was undetectable in 69 cases (21.2%) and detectable over wide concentrations in the other 257 patients (78.8%) prior to LT. Polymerase chain reaction analysis of the store blood samples detected HBV DNA in all patients, with 159 patients (48.9%) showing concentrations > 100 IU/mL. Post-transplant HBV regimens during the first year included combination therapy in 196 (60.1%), hepatitis B immunoglobulin (HBIG) monotherapy in 121 (37.1%), and antiviral monotherapy in 9 (2.8%). In the second post-transplant year, these regimens had changed to combination therapy in 187 (57.4%), HBIG monotherapy in 112 (34.4%), and antiviral monotherapy in 27 (8.3%). Trough antibody to hepatitis B surface antigen titers > 500 IU/mL and >1,000 IU/mL were observed in 61.7% and 25.2%, respectively. The mean simulative half-life of HBIG was 21.6 ¡¾ 4.3 days with a median 17.7 days. Up to 2-year follow-up period, HCC recurrence and HBV recurrence developed in 18 (5.5%) and 6 (1.8%), respectively. HCC recurrence developed in 3 of 6 patients with HBV recurrence.
Conclusion: Combination therapy is the mainstay of HBV prophylaxis protocols in a majority of Korean LT centers, but HBIG was often administered excessively. Individualized optimization of HBIG treatments using SHL is necessary to adjust the HBIG infusion interval.
|
|
KEYWORD
|
|
Hepatitis B Virus, Recurrence, Liver Transplantation, Hepatitis B Immunoglobulin, Antiviral Agent
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|